1.30
+3.17%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MaxCyte
From its filings with the US Securities and Exchange Commission
MaxCyte is based in Rockville, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MXCT. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $33.0m and a net loss of $44.6m. At that date it held total assets of $202.5m and shareholders' equity of $171.5m.
We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells.
Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.
With increased knowledge of cell complexity and systems biology in the scientific community, researchers have sought to leverage or repurpose cell functions and/or machinery for research or therapeutic purposes. The ability to engineer living cells by introducing foreign molecules, such as gene editing systems and transgenes, has led to a revolution in biological research and resulted in numerous biological discoveries. Living human cells can also be engineered ex vivo, or outside the body, where they are repaired or reprogrammed to fight disease. In this case, the engineered cell itself is the drug.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Mar 2016
- Employees
- 65
- Website
- maxcyte.com ↗
- Head office
- 9713 KEY WEST AVENUE,, ROCKVILLE, MD, 20850
- Incorporated in
- DE
- Classification
- Services-Commercial Physical & Biological Research
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Richard DouglasNon-Executive Independent Chairman of the Board$289,987
- Mr. Maher MasoudPresident, Chief Executive Officer, Director, since 2020$3.6m
- Mr. Douglas SwirskyChief Financial Officer$1.7m
- Mr. David SandovalSenior Vice President, General Counsel, Corporate Secretary
- Dr. Yasir Al-WakeelNon-Executive Independent Director$249,987
- Mr. Patrick BalthropNon-Executive Independent Director$254,987
- Mr. William BrookeNon-Executive Independent Director$267,487
- Ms. Cynthia CollinsNon-Executive Independent Director$409,966
- Mr. Stanley ErckNon-Executive Independent Director$262,487
- Ms. Rekha HemrajaniNon-Executive Independent Director$264,987
- Mr. John JohnstonNon-Executive Independent Director$249,987
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 31
- Social
- 58
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MaxCyte Inc has a strong reputation in the biotechnology industry, known for its innovative cell transfection technology.
- The company has a solid intellectual property portfolio, protecting its technology and giving it a competitive edge.
- MaxCyte Inc has established strategic partnerships with leading pharmaceutical companies, allowing for collaborative research and development opportunities.
- With a skilled and experienced workforce, MaxCyte Inc possesses the necessary expertise to drive its growth and success.
Weaknesses
- MaxCyte Inc's operations heavily rely on a few key clients, creating a potential risk of loss if these clients reduce their business or terminate contracts.
- The company may face challenges in penetrating new markets due to intense competition and regulatory hurdles in the biotechnology industry.
- MaxCyte Inc's financial performance is not as strong as some of its competitors, potentially limiting its ability to invest in research and development.
Opportunities
- The growing demand for cell-based therapies presents an excellent opportunity for MaxCyte Inc to expand its market presence and increase revenues.
- The company can leverage its technology to target the gene editing market, which is experiencing significant growth and offers promising commercial potential.
- MaxCyte Inc can explore partnerships with academic institutions and research organizations to tap into emerging scientific advancements and broaden its product offerings.
Threats
- MaxCyte Inc faces the risk of new entrants in the cell transfection technology market, which may challenge its market share and competitive position.
- Changes in government regulations or policies related to biotechnology and gene editing could impact the company's operations and hinder its growth prospects.
- The global economic conditions and fluctuations in exchange rates pose a threat to MaxCyte Inc's international operations and revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.